Physicians Expect To Decrease First- And Second- Line Use Of Vytorin In Wake Of ENHANCE Trial Results, According To Study By GfK Market Measures

Reacting to the release of the ENHANCE trial results that showed Vytorin, a combination of the statin simvastatin (Zocor) and ezetimibe (Zetia), provides no benefit over simvastatin alone in preventing the progress of arterial plaque buildup, physicians indicate they will shift Vytorin heavily to third-line, rather than first- or second- line use, in treating patients at risk for coronary heart disease, according to new research by GfK Market Measures.

More: continued here

Filed under: Cardiovascular on February 19th, 2008